About Matrilin-3
Matrilin-3 (MATN3) is a protein
from Homo sapiens identified by UniProt accession
O15232, 486 residues long.
MolForge cross-references it against 0 known binders and
192 disease associations.
Target properties
| Protein name | Matrilin-3 |
| UniProt accession | O15232 |
| Gene | MATN3 |
| Organism | Homo sapiens |
| Length | 486 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (192)
Diseases linked to this target (Open Targets).
- multiple epiphyseal dysplasia type 5 · score 0.83
- spondyloepimetaphyseal dysplasia, matrilin-3 type · score 0.62
- multiple epiphyseal dysplasia · score 0.51
- multiple epiphyseal dysplasia, Beighton type · score 0.46
- body height · score 0.45
- osteoarthritis · score 0.39
- appendicular lean mass · score 0.39
- minimal erythema dose · score 0.38
- spondyloepimetaphyseal dysplasia · score 0.37
- Spondyloepimetaphyseal dysplasia · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15232-F1 | alphafold | PREDICTED | 79.35 | — |
Amino-acid sequence (486 residues)
MPRPAPARRL PGLLLLLWPL LLLPSAAPDP VARPGFRRLE TRGPGGSPGR RPSPAAPDGA PASGTSEPGR ARGAGVCKSR PLDLVFIIDS SRSVRPLEFT KVKTFVSRII DTLDIGPADT RVAVVNYAST VKIEFQLQAY TDKQSLKQAV GRITPLSTGT MSGLAIQTAM DEAFTVEAGA REPSSNIPKV AIIVTDGRPQ DQVNEVAARA QASGIELYAV GVDRADMASL KMMASEPLEE HVFYVETYGV IEKLSSRFQE TFCALDPCVL GTHQCQHVCI SDGEGKHHCE CSQGYTLNAD KKTCSALDRC ALNTHGCEHI CVNDRSGSYH CECYEGYTLN EDRKTCSAQD KCALGTHGCQ HICVNDRTGS HHCECYEGYT LNADKKTCSV RDKCALGSHG CQHICVSDGA ASYHCDCYPG YTLNEDKKTC SATEEARRLV STEDACGCEA TLAFQDKVSS YLQRLNTKLD DILEKLKINE YGQIHR
Explore Matrilin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets